Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136898 · ClinicalTrials.gov registry record · Phase 3
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
A Phase 3 study of Bladder Cancer and Urothelial Carcinoma, sponsored by UroGen Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT05136898 is a Phase 3 study of Bladder Cancer and Urothelial Carcinoma that has completed, run by UroGen Pharma. The registered enrollment target is 8 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05136898, a Phase 3 study of Bladder Cancer and Urothelial Carcinoma, has completed, sponsored by UroGen Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Conditions Studied
Interventions
- DRUG UGN-102
Study Locations (5)
Alabama
- Urology Centers of Alabama (UCA) - Homewood
Indiana
- Indiana University School of Medicine - Indianapolis
North Carolina
- Medication Management - Greensboro
Tennessee
- Urology Associates, P.C. - Nashville
Virginia
- Virginia Urology - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05136898
The ClinicalTrials.gov registry entry for NCT05136898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is UroGen Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which UGN-102 is the first listed.
NCT05136898 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05136898 about?
NCT05136898 is a clinical study titled "Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)". This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG...
What is the current status of trial NCT05136898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2021-11-30. Estimated completion is 2023-02-02.
What conditions does trial NCT05136898 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder.
What interventions are being tested in trial NCT05136898?
The interventions under investigation include: UGN-102 (DRUG).
Who is sponsoring clinical trial NCT05136898?
This trial is sponsored by UroGen Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05136898 being conducted?
This trial has 5 study locations across Alabama, Indiana, North Carolina, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.